SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/04/21 Y-mAbs Therapeutics, Inc. 10-Q 9/30/21 76:7.4M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 1.27M 2: EX-31.1 Certification -- §302 - SOA'02 HTML 28K 3: EX-31.2 Certification -- §302 - SOA'02 HTML 27K 4: EX-32.1 Certification -- §906 - SOA'02 HTML 23K 5: EX-32.2 Certification -- §906 - SOA'02 HTML 23K 12: R1 Document and Entity Information HTML 75K 13: R2 Consolidated Balance Sheets HTML 116K 14: R3 Consolidated Balance Sheets (Parenthetical) HTML 34K 15: R4 Consolidated Statements of Net Loss and HTML 92K Comprehensive Loss 16: R5 Consolidated Statements of Changes in HTML 95K Stockholders' Equity 17: R6 Consolidated Statements of Cash Flows HTML 98K 18: R7 Organization and Description of Business HTML 24K 19: R8 Basis of Presentation HTML 29K 20: R9 Summary of Significant Accounting Policies HTML 78K 21: R10 Product Revenue HTML 58K 22: R11 Net Loss Per Share HTML 48K 23: R12 Inventory HTML 38K 24: R13 Accrued Liabilities HTML 42K 25: R14 License Agreements and Commitments HTML 150K 26: R15 Stockholders' Equity HTML 33K 27: R16 Share-Based Compensation HTML 92K 28: R17 Related Party Transactions HTML 25K 29: R18 Income Taxes HTML 27K 30: R19 Other Benefits HTML 24K 31: R20 Gain From Sale of Priority Review Voucher HTML 24K 32: R21 Summary of Significant Accounting Policies HTML 104K (Policies) 33: R22 Summary of Significant Accounting Policies HTML 59K (Tables) 34: R23 Product Revenue (Tables) HTML 52K 35: R24 Net Loss Per Share (Tables) HTML 47K 36: R25 Inventory (Tables) HTML 39K 37: R26 Accrued Liabilities (Tables) HTML 41K 38: R27 License Agreements and Commitments (Tables) HTML 141K 39: R28 Share-Based Compensation (Tables) HTML 84K 40: R29 BASIS OF PRESENTATION - Accumulated deficit HTML 25K (Details) 41: R30 BASIS OF PRESENTATION - Secondary public offering HTML 34K (Details) 42: R31 BASIS OF PRESENTATION - Cash and cash equivalents HTML 24K (Details) 43: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 29K Concentration of Credit Risk (Details) 44: R33 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 40K Value Measurement (Details) 45: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 49K Revenue Recognition - License Revenue (Details) 46: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K Segment (Details) 47: R36 PRODUCT REVENUE - Discounts and Allowances HTML 59K (Details) 48: R37 PRODUCT REVENUE - Concentrations (Details) HTML 33K 49: R38 NET LOSS PER SHARE - Basic and diluted (Details) HTML 49K 50: R39 NET LOSS PER SHARE - Anti-dilutive securities HTML 23K (Details) 51: R40 Inventory (Details) HTML 28K 52: R41 Accrued Liabilities (Details) HTML 36K 53: R42 LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and HTML 66K MabVax License Agreement (Details) 54: R43 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 40K agreements (Details) 55: R44 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 64K agreements (Details) 56: R45 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 31K (Details) 57: R46 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 38K maturities (Details) 58: R47 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 26K and discount rate (Details) 59: R48 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 40K Preferred Stock (Details) 60: R49 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 77K non-employees (Details) 61: R50 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 38K (Details) 62: R51 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 31K 63: R52 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 41K 64: R53 SHARE-BASED COMPENSATION - Stock option expense HTML 34K (Details) 65: R54 SHARE-BASED COMPENSATION - Stock option activity HTML 64K (Details) 66: R55 SHARE-BASED COMPENSATION - Stock option HTML 28K unrecognized compensation (Details) 67: R56 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 62K Activity (Details) 68: R57 Related Party Transactions (Details) HTML 39K 69: R58 INCOME TAXES - Expense (Details) HTML 35K 70: R59 INCOME TAXES - Uncertain tax positions (Details) HTML 23K 71: R60 Other Benefits (Details) HTML 29K 72: R61 Gain From Sale of Priority Review Voucher HTML 34K (Details) 74: XML IDEA XML File -- Filing Summary XML 135K 11: XML XBRL Instance -- ymab-20210930x10q_htm XML 1.65M 73: EXCEL IDEA Workbook of Financial Reports XLSX 86K 7: EX-101.CAL XBRL Calculations -- ymab-20210930_cal XML 132K 8: EX-101.DEF XBRL Definitions -- ymab-20210930_def XML 529K 9: EX-101.LAB XBRL Labels -- ymab-20210930_lab XML 1.10M 10: EX-101.PRE XBRL Presentations -- ymab-20210930_pre XML 841K 6: EX-101.SCH XBRL Schema -- ymab-20210930 XSD 161K 75: JSON XBRL Instance as JSON Data -- MetaLinks 340± 491K 76: ZIP XBRL Zipped Folder -- 0001558370-21-014548-xbrl Zip 302K
Download this zipped .zip folder | |
Files: | ymab-20210930.xsd ymab-20210930_cal.xml ymab-20210930_def.xml ymab-20210930_lab.xml ymab-20210930_pre.xml ymab-20210930x10q.htm ymab-20210930xex31d1.htm ymab-20210930xex31d2.htm ymab-20210930xex32d1.htm ymab-20210930xex32d2.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/06/21 Y-mAbs Therapeutics, Inc. 10-Q 3/31/21 76:6.3M Toppan Merrill Bridge/FA 11/05/20 Y-mAbs Therapeutics, Inc. 10-Q 9/30/20 68:6.7M Toppan Merrill Bridge/FA 9/26/18 Y-mAbs Therapeutics, Inc. 8-K:5,7,9 9/25/18 4:284K Toppan Merrill/FA 8/24/18 Y-mAbs Therapeutics, Inc. S-1 31:12M Toppan Merrill-FA |